Cargando…

Adjuvant therapy for high-risk melanoma

Detalles Bibliográficos
Autor principal:	Eggermont, Alexander M.M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2013
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4041312/ https://www.ncbi.nlm.nih.gov/pubmed/26217119 http://dx.doi.org/10.1016/j.ejcsup.2013.07.014

Ejemplares similares

Utility of adjuvant systemic therapy in melanoma
por: Eggermont, A. M. M., et al.
Publicado: (2009)

Systemic adjuvant therapy for high-risk cutaneous melanoma
por: Kobeissi, Iyad, et al.
Publicado: (2022)

Adjuvant Therapy: Melanoma
por: Davar, Diwakar, et al.
Publicado: (2011)

Adjuvant crizotinib in high-risk uveal melanoma following definitive therapy
por: Khan, Shaheer, et al.
Publicado: (2022)

Deselecting Melanoma Patients for Sentinel Lymph Node Biopsy During COVID-19: Clinical Utility of Tumor Molecular Profiling
por: Meves, Alexander, et al.
Publicado: (2020)

What can we learn from phase II adjuvant trials in melanoma?
por: Keilholz, U, et al.
Publicado: (2000)

High frequency of brain metastases after adjuvant therapy for high‐risk melanoma
por: Samlowski, Wolfram E., et al.
Publicado: (2017)

Adjuvant Ipilimumab in High-Risk Uveal Melanoma
por: Fountain, Eric, et al.
Publicado: (2019)

Adjuvant Therapy for High-Risk Melanoma: An In-Depth Examination of the State of the Field
por: Eljilany, Islam, et al.
Publicado: (2023)

Adjuvant and neoadjuvant therapies in melanoma
por: Lim, Kok Haw Jonathan, et al.
Publicado: (2020)

Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
por: Salans, Mia, et al.
Publicado: (2021)

Adjuvant therapy for melanoma: How should we respond to high-dose interferon?
por: de Takats, P. G., et al.
Publicado: (1998)

An update on adjuvant systemic therapies in melanoma
por: Samuel, Evangeline, et al.
Publicado: (2019)

Adjuvant interferon alpha 2b in high risk melanoma – the Scottish study
por: Cameron, D A, et al.
Publicado: (2001)

Adjuvant Therapy for Melanoma: Past, Current, and Future Developments
por: Testori, Alessandro A. E., et al.
Publicado: (2020)

Impact of Circulating and Tissue Biomarkers in Adjuvant and Neoadjuvant Therapy for High-Risk Melanoma: Ready for Prime Time?
por: Indini, Alice, et al.
Publicado: (2021)

Considering adjuvant therapy for stage II melanoma
por: Poklepovic, Andrew S., et al.
Publicado: (2019)

Adjuvant Treatment of Melanoma
por: Moreno Nogueira, J. A., et al.
Publicado: (2013)

Adjuvant therapy of melanoma with interferon: lessons of the past decade
por: Ascierto, Paolo A, et al.
Publicado: (2008)

A pilot study of interferon-alpha-2b dose reduction in the adjuvant therapy of high-risk melanoma
por: Suarez-Kelly, Lorena P., et al.
Publicado: (2019)

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015)

Recent advances in adjuvant therapy for patients with melanoma
por: Weber, Jeffrey
Publicado: (2018)

Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe: a model-based economic evaluation
por: Mulder, E.E.A.P., et al.
Publicado: (2021)

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
por: Corrie, P G, et al.
Publicado: (2018)

Adjuvant interferon in the treatment of melanoma
por: Middleton, M R
Publicado: (1999)

Adjuvant interferon in the treatment of melanoma
por: Kirkwood, J M
Publicado: (2000)

Targeted Therapy; From Advanced Melanoma to the Adjuvant Setting
por: Ahn, Antonio, et al.
Publicado: (2013)

Current Landscape and Open Questions on Adjuvant Therapies in Melanoma
por: De Falco, Vincenzo, et al.
Publicado: (2021)

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
por: Corrie, P G, et al.
Publicado: (2019)

Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti–PD-1 Therapy for High-Risk Resected Melanoma
por: Goodman, Rachel S., et al.
Publicado: (2023)

Staging of cutaneous melanoma
por: Mohr, P., et al.
Publicado: (2009)

Adherence to COVID-19 vaccines in cancer patients: promote it and make it happen!
por: Curigliano, Giuseppe, et al.
Publicado: (2021)

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy
por: Eckardt, Julia, et al.
Publicado: (2022)

Epidemiology of invasive cutaneous melanoma
por: MacKie, R. M., et al.
Publicado: (2009)

Adjuvant interferon in the treatment of melanoma – reply
por: Middleton, M R
Publicado: (2000)

Adjuvant radiation therapy in metastatic lymph nodes from melanoma
por: Bibault, Jean-Emmanuel, et al.
Publicado: (2011)

Treatment Approaches for Melanomas That Relapse After Adjuvant or Neoadjuvant Therapy
por: Ng, Gary, et al.
Publicado: (2022)

Adjuvant interferon in melanoma – a resurrection?
por: Middleton, M R, et al.
Publicado: (2001)

A Multi-Factorial Genetic Model for Prognostic Assessment of High Risk Melanoma Patients Receiving Adjuvant Interferon
por: Wang, Ena, et al.
Publicado: (2012)

Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis
por: Bhave, Prachi, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sjrkm7eomutodovhv9l8nk0qcm